In his weekly clinical update, Dr. Griffin discusses a microbiologist who was harassed during COVID pandemic sues university, use of inactivated poliovirus vaccine for poliovirus outbreak response, safety and immunogenicity of bivalent rsvpref vaccine coadministered with seasonal inactivated influenza vaccine in older adults, coffee as a dietary strategy to prevent SARS-CoV-2 infection, enrollment of pediatric patients in COVID-19 interventional trials, vaccination, immunity, and the changing impact of COVID-19 on infant health, COVID-19 vaccine effectiveness against post- COVID -19 condition among 589722 individuals in Sweden, repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting, protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults, the Novavax heterologous COVID booster demonstrates lower reactogenicity than mRNA vaccines, T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19, oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China, and how COVID-19 convalescent plasma therapy decreases inflammatory cytokines, therapeutic heparin in non-ICU patients hospitalized for COVID-19 in the ACTIV-4a trial.

Click arrow to play

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Microbiologist who was harassed during COVID pandemic sues university (Nature)
• Use of inactivated poliovirus vaccine for outbreak response (The Lancet)
• Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with Influenza vaccine (CID)
• Coffee as a dietary strategy to prevent SARS-CoV-2 infection (BMC)
• Enrollment of pediatric patients in COVID-19 interventional trials (JAMA)
• Vaccination, immunity, and the changing impact of COVID-19 on infant health (PNAS)
• COVID-19 vaccine effectiveness against post- COVID -19 condition (BMJ)
• Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting (Nature)
• Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes (CID)
• Novavax heterologous COVID booster demonstrates lower reactogenicity than mRNA (JID)
• T-cell responses to SARS-CoV-2 infection and vaccination reduce risk of severe COVID-19 (STM)
• Oral VV116 vs placebo in patients with mild-to-moderate COVID-19 in China (The Lancet)
• COVID-19 convalescent plasma therapy decreases inflammatory cytokines (MS)
• Therapeutic heparin in non-ICU patients hospitalized for COVID-19 in the ACTIV-4a trial (Chest)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV on TWiV 1066
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

TWiV reviews ban on gain-of-function research by the House, chronic wasting disease in Tennessee deer, nOPV2 causing paralysis in children, and an outbreak of feline infectious peritonitis in Cyprus caused by a new recombinant coronavirus.

Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• MicrobeTV Discord Server
• MicrobeTV store at Cafepress
• Global Scholar Travel Awards (ASV)
• Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
• The New City by Dickson Despommier
• House approves ban on gain-of-function research (Science)
• Virology under the microscope (J Virol)
• CWD detected in another Tennessee county (CIDRAP)
• Polio eradication: Do no harm (Science)
• nOPV2 causes polio (MMWR)
• How is nOPV2 doing? (Polioeradication.org)
• Feline infectious peritonitis caused by recombinant coronavirus (bioRxiv)
• New feline coronavirus kills thousands of cats (Science)
• Feline coronavirus with Gary Whittaker (TWiV 963)
• Letters read on TWiV 1065
• Timestamps by Jolene. Thanks!

Dickson – Climate Action and How to find joy in climate action Brianne – A Virus that Generates Electricity Kathy – Intolerable Genius: Berkeley’s most controversial Nobel laureate Rich – Programmed DNA Elimination (PDE): Quanta; Current Biology Alan – KBDfans mechanical keyboard kits Vincent – The Covid Vaccine Windfall Turns for Pfizer and Moderna

Meika – Iceland Eruption or not?

Intro music is by Ronald Jenkees

Send your virology questions and comments to [email protected]

In his weekly clinical update, Dr. Griffin discusses progress toward measles elimination, risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs, symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals, late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial, higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19, recombinant C1 inhibitor in the prevention of severe COVID-19, and Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Progress toward measles elimination (CDC)
• Risk of severe COVID-19 despite vaccination in patients using immune-suppressive drugs (TID)
• Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to untreated individuals (CID)
• Late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial (JID)
• Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19 (JAMA)
• Recombinant C1 inhibitor in the prevention of severe COVID-19 (FII)
• Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with SARS-CoV-2 disease course (BMC)
• Contribute to our MicrobeTV fundraiser at PWB 37:55
• Letters read on TWiV on TWiV 1062 38:16
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

Kevin Messacar visits the Incubator to discuss his career as a pediatric infectious disease physician, and his work on enteroviruses that are associated with acute flaccid myelitis and other diseases.

Host: Vincent Racaniello

Guest: Kevin Messacar

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• MicrobeTV Discord Server
• MicrobeTV store at Cafepress
• Global Scholar Travel Awards (ASV)
• Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
• Emergence of EV-D68 (Microbio Spectr)
• 2014 outbreak of EV-D68 (J Med Virol)
• EV-D68 shedding in households (Emerg Inf Dis)
• EV-A71 outbreak in Colorado (Lancet Inf Dis)

Intro music is by Ronald Jenkees

Send your virology questions and comments to [email protected]

In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Coverage with selected vaccines and exemption from school vaccine requirements among (CDC)
• Seasonality of endemic COVID-19 (Virology)
• mRNA SARS-CoV-2 vaccination before vs during pregnancy and Omicron infection among infants (JAMA)
• Extracting symptoms from responses using ChatGPT among COVID-19 cases (CMI)
• SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
• Optimization of antiviral therapy in immunocompromised COVID-19 patients (ClinicalTrials)
• A study to learn about nirmatrelvir/ritonavir in people with COVID-19 and a compromised immune system (ClinicalTrials)
• Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection (EJP)
• Effect of neutralizing monoclonal antibody treatment on virologic and immunologic biomarkers in patients with COVID-19 (JID)
• SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV on TWiV 1062
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

TWiV reveals a prediction of the expected endemic seasonality of COVID-19, based on circulation of human coronaviruses, and ecological clearance of vaccine-targeted human papillomaviruses and an increase in circulation of non-targeted virus types.

Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, and Kathy Spindler

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• MicrobeTV Discord Server
• MicrobeTV store at Cafepress
• Global Scholar Travel Awards (ASV)
• Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
• The New City by Dickson Despommier
• Seasonality of endemic COVID-19 (mBio)
• Diversity of non-vaccine targeted HPVs (Cell Host Microbe)
• Wart’s up doc? (TWiV 126)
• Letters read on TWiV 1061
• Timestamps by Jolene. Thanks!

Dickson – 2023 expected to be hottest year on record after warmest October ever Kathy – You can see the ISS toolbag with binoculars, Billy Collins wikipedia, What dogs think (probably) Alan – Landmark case to get sanitation declared a civil right Vincent – SciComm Studios

Charmaine – Petition fo National Science Appreciation Day Peter – Let’s eradicate polio this winter

Intro music is by Ronald Jenkees

Send your virology questions and comments to [email protected]

In his weekly clinical update, Dr. Griffin discusses stress in America 2023, CDC expanding testing of international air traveler samples to include flu, RSV, and other respiratory viruses, missed opportunities for preventing congenital syphilis, intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and omicron BA.2 variant in Hong Kong, T-cell immunity against severe acute respiratory syndrome coronavirus 2 measured by an interferon-γ release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with delta or omicron variants, masks during pandemics caused by respiratory pathogens, behavioral factors and SARS-CoV-2 transmission heterogeneity within a household cohort in Costa Rica, convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients, and olfactory and gustatory function 3 years after mild COVID-19.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Stress in America 2023 (APA)
• CDC expands testing of international air traveler samples to include flu RSV, and other respiratory viruses (CDC)
• Missed opportunities for preventing congenital syphilis (CDC)
• Intrinsic and effective severity of COVID-19 case infected with BA.2 variant (JID)
• Masks during pandemics caused by respiratory pathogens (JAMA)
• Behavioral factors and SARS-CoV-2 transmission within a household cohort (Nature)
• Convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients (NEJM)
• Olfactory and gustatory function 3 years after mild COVID-19 (JAMA)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV on TWiV 1060
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

On this episode of TWiV we discuss unusual properties of monoclonal antibodies: one that that binds the receptor attachment site and blocks infection with all three poliovirus serotypes, and others that inhibit Ebolavirus spread from cell to cell.

Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Angela Mingarelli

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• MicrobeTV Discord Server
• MicrobeTV store at Cafepress
• Global Scholar Travel Awards (ASV)
• Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
• Monoclonal antibody neutralizes all three poliovirus serotypes (Nat Comm)
• Blocking Ebolavirus intercellular spread (Cell Rep)
• Letters read on TWiV 1059
• Timestamps by Jolene. Thanks!

Dickson – Climate Science Angela – Spider Ballooning (Wikipedia) Kathy – Richard Harris Art Collection Rich – “The Murderbot Diaries” by Martha Wells Alan – Old Gods of Appalachia Vincent – Poetry Foundation

Intro music is by Ronald Jenkees

Send your virology questions and comments to [email protected]

In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-BN vaccination, newborn and early infant outcomes following maternal COVID-19 vaccination during pregnancy, duration of SARS-CoV-2 culturable virus shedding in children, prescribing outcomes in outpatients treated with nirmatrelvir–ritonavir for COVID-19 in an interdisciplinary community clinic, Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients, optimal duration of systemic corticosteroids in COVID-19 treatment, association between Guillain-Barré syndrome and COVID-19 infection and vaccination, SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration, Transplanting candidates with COVID-19, and favorable experience of transplant strategy including liver grafts from COVID-19 donors.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Routine vaccination coverage (CDC)
• Outbreak of invasive Group A Streptococcus in children (PIDS)
• Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 (Nature)
• Outcomes of SARS-CoV-2 omicron variant infections compared with seasonal influenza and RSV infections in adults (CID)
• Remdesivir is associated with reduced mortality in COVID-19 patients requiring oxygen (OFID)
• Effectiveness of nirmatrelvir/ritonavir against the development of Post–COVID-19 conditions among U.S. veterans (AIM)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV 1058
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

Klaus Früh visits the Incubator to discuss his career and his work on cytomegalovirus-vectored vaccines which are unique in their ability to persistently maintain an immune shield of effector memory T cells, including highly unconventional MHC-II and MHC-E restricted CD8+ T cells.

Host: Vincent Racaniello, Rich Condit, and Brianne Barker

Guest: Klaus Früh

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• MicrobeTV Discord Server
• MicrobeTV store at Cafepress
• Spike shirts at vaccinated.us (promo code Microbetv)
• Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
• HCMV-based attenuated vaccine platform (Sci Rep)
• HLA-E-restricted, Gag-specific CD8+ T cells suppress HIV-1 infection (Sci Immunol)
• RhCMV/SIV vaccine shows long-term efficacy against SIV challenge (Sci Transl Med)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your virology questions and comments to [email protected]